Drug Profile
Research programme: antisense oligonucleotide MDM2 - Aceragen
Alternative Names: GEM 240; HDMAS5; Research programme: anti-MDM2 antisense oligonucleotidesLatest Information Update: 20 Jan 2023
Price :
$50
*
At a glance
- Originator Idera Pharmaceuticals; Johns Hopkins University; University of Alabama
- Developer Aceragen; Sanofi; University of Alabama
- Class Antineoplastics; Nucleotides
- Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c mdm2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer